Sage Journals: Discover world-class research

Abstract

Objective

Evaluate a low-urapidil protocol (30 µg/kg bolus + 20 µg/kg/h infusion) on oxidative stress, inflammation, apoptosis, and matrix metalloproteinase−9 (MMP-9)-mediated matrix remodeling in a rat renal ischemia-reperfusion (I/R) injury model.

Methods

32 male Wistar rats were randomized into control (CR), sham (SH), I/R, and I/R + Urapidil (UR) groups. The CR group received no treatment, the SH group underwent laparotomy and intraperitoneal normal saline, the I/R group underwent laparotomy with 30-min of aortic clamping and 24 h of reperfusion, and the UR group received urapidil starting at 1 h before 30-min of aortic clamping (ischemia), followed by 24 h of reperfusion. Assessments included serum creatinine/urea, oxidative markers (total antioxidant status [TAS, total oxidant status [TOS]), inflammatory cytokines (tissue necrosis factor-alpha [TNF-α], interleukin [IL]-1β, IL-6, and MMP-9) via enzyme-linked immunosorbent assay, renal histopathology (hematoxylin and eosin staining), and immunohistochemistry (H-scores for endothelial nitric oxide synthase [eNOS], caspase-3, TNF-α, IL-1β, IL-6, and MMP-9).

Results

I/R significantly increased serum creatinine, urea, TNF-α, IL-1β, and TOS, and depleted TAS, indicating severe injury, oxidative stress, and inflammation. Extensive tubular necrosis, vacuolization, and edema were also observed. Immunohistochemistry revealed elevated levels of eNOS, caspase-3, cytokines, and MMP-9. Urapidil pretreatment effectively normalized serum creatinine/urea, restored TAS, reduced TOS and cytokines (TNF-α, IL-1β, IL-6) to baseline, and markedly alleviated histopathological damage. Urapidil significantly suppressed I/R-induced elevations in oxidative (eNOS), apoptotic (caspase-3), and inflammatory markers, and MMP-9 expression.

Conclusion

Low-dose urapidil confers significant protection against renal I/R injury by mitigating oxidative stress, inflammation, apoptosis, and MMP-9-mediated matrix degradation. The efficacy at microgram doses highlights its potential as a clinically relevant nephroprotective agent.

Keywords

acute kidney injury chronic kidney injury renal ischemia reperfusion injury urapidil oxidative stress

Introduction

Ischemic reperfusion (I/R) injury is a serious clinical condition that occurs when blood flow to tissues is temporarily interrupted and then restored.^1,2 This damage causes significant functional and cellular losses in various organs. Renal I/R injury is considered an important cause of acute kidney injury (AKI) and is frequently encountered during kidney transplantation, cardiovascular surgery, and shock.^3,4 Recently, many complex mechanisms have been suggested to play a role in the pathophysiology of renal I/R injury, such as oxidative stress, inflammation, apoptosis, and ferroptosis.^5,6 Among these, the increased production of reactive oxygen species (ROS) and insufficient antioxidant defense systems are considered critically important.⁷

Urapidil (UP) blocks alpha-1 adrenergic receptors and activates serotonin (5-HT1A) receptors, helping to lower blood pressure by decreasing blood vessel resistance. The antioxidant, anti-inflammatory, and anti-apoptotic properties of UP have been previously investigated in various experimental I/R models, such as testicular torsion, ovarian torsion, intestinal ischemia, and cerebral ischemia.^8,9 However, the number of studies examining the effects of UP in renal I/R injury is limited, and existing studies generally include intraperitoneal pre-ischemic dose applications at the milligram level.¹⁰ Approaches such as the use of low-microgram doses, continuous intraperitoneal infusion, or application at earlier time points before ischemia have not yet been evaluated. In addition to the classically evaluated inflammatory (tissue necrosis factor-alpha [TNF-α], interleukin [IL]-1β), oxidative stress (total oxidant status [TOS], total antioxidant status [TAS]) and apoptosis (caspase-3) markers in renal I/R injury, the effects on new and different molecular mechanisms such as cellular stress responses (e.g., Nrf2, NF-κB), mitochondrial function markers, and ferroptosis have not been sufficiently investigated. UP has been shown to increase the level of nuclear factor-erythroid 2-related factor 2 (Nrf2), which controls the activity of enzymes involved in the antioxidant system and plays an important role in I/R damage.^11,12 To address these gaps in the existing literature, in this study we aimed to comprehensively evaluate the effects of UP administered at a low microgram dose (30 µg/kg loading dose followed by 20 µg/kg/h continuous intraperitoneal infusion) on oxidative stress, inflammation, apoptosis, and matrix regulatory factors in the renal tissue of a renal I/R model. Through this, we aim to contribute to a better understanding of the renal protective mechanisms of UP and to evaluate its clinical potential by presenting a new dose and administration method.

Materials and methods

Study design

In this study, we used 4-month-old male Wistar albino rats (n = 32) weighing 250–300 g. These rats were randomly divided into four groups, each comprising eight rats: control (CR, group 1), sham (SH, group 2), I/R (I/R, group 3), and I/R + UP (UR, group 4).

Ethical approval

The Afyon Kocatepe University Experimental Animal Ethics Committee approved this study (approval number: 49533702/101; approval date: November 10, 2023). The experimental rats were placed in cages under standard laboratory conditions that included a 12 h light/dark cycle, at 22°C ± 2°C, and a humidity level of 55% ± 5%. The rats were provided ad libitum food and water.^13,14 The study adhered to the ARRIVE reporting guidelines¹⁵ and complied with the Guide for the Care and Use of Laboratory Animals, 8th Edition.¹⁶ Every effort was made to minimize the number of animals used and reduce animal suffering.

Anesthesia

All rats were premedicated by intramuscular administration of 13 mg/kg Xylazine HCl ((Xylazinbio, %2, 50 ml Vial, Bioveta, Bioveta, a.s., Komenskeho Czech Republic). General anesthesia with Ketamine HCl ((Ketasol, %10, 10 ml vial; İnterhas Medical and Chemical Products Industry and Inc. Ankara-Turkey) was administered intramuscularly at a dose of 87 mg/kg intramuscularly.¹⁷

Surgical procedure

After dissection of the abdominal cavity, the aorta was located and exposed from its origin to the distal bifurcation of the left renal artery, where it was proximally clamped. Similar to other ischemia-inducing methods, I/R injury was induced by infrarenal clamping of the abdominal aorta (Aesculap, Tuttlingen, Germany), which has been shown to cause I/R injury^18–21 In a previous experimental study,²² a dose of 20 µg/(kg⋅h) UP, the maximum dose that does not impact mean blood flow in the kidneys, arterial blood pressure, and heart rate, was administered intraperitoneally. The pulse of the femoral artery was not detected throughout the 30-min ischemia phase; however, it returned on reperfusion.¹⁷

Groups and the I/R model

Group 1 (n = 8), CR: rats in this group received no treatment and were euthanized after 24 h. Rats were euthanized with an intraperitoneal injection of 150 mg/kg of thiopental sodium.

Group 2 (n = 8), SH: Median laparotomy was performed on the rats under general anesthesia. The renal artery and pedicle were then dissected. After this, the abdomen was closed and 5% of the body weight isotonic sodium chloride (0.9%) was intraperitoneally administered. No other treatments were performed, and the rats were sacrificed after 24 h.

Group 3 (n = 8), I/R: The abdominal aorta of the rats was clamped with an infrarenal bulldog clamp for 30 min. Thereafter, the clamp was detached, and the abdomen was sutured following the standard protocol. The rats in this group were not administered any drug treatment before or after surgery. The rats were sacrificed after 24 h.

Group 4 (n = 8), UR: 25 mg/5 mL UP solution (Vem Pharmaceutical Industry and Trade Inc. Istanbul, Turkey) was administered intraperitoneally using an infusion pump (SYS-70 Shanghai International Holding Corp. GmbH () Hamburg, Germany) at a dose of 30 mcg/kg 1 h before the operation. During the operation, it was administered by infusion at a dose of 20 mcg/kg until the bulldog clamp was removed (during ischemia). The rats were sacrificed after 24 h.

Euthanasia

After a 24-hour reperfusion period all rats were deeply anesthetized via intraperitoneally Thiopental Sodium 150 mg/kg (Pental, 0,5 g fl. İ.E. Ulagay Drug Manifacture Türk A.Ş. Istanbul-TURKEY) and subsequently euthanized by overdose.

Source of animals

All rats were certified Wistar Albino rats obtained from the licensed breeding colony of the Afyon Kocatepe university Experimental Animals Application and Research Center. All procedures were conducted in the same facility.

Histopathological examination

Re-laparotomy was performed under anesthesia, as in the I/R procedure, and a left nephrectomy was performed. The renal capsule was excised. Half of each kidney was preserved in 10% formalin for histopathological examination. Hematoxylin and eosin (HE) staining and scoring were performed to determine the morphological effects of UP on I/R injury. The expressions of endothelial nitric oxide synthase (eNOS) for oxidative stress; caspase-3 for apoptosis; and IL-1β, IL-6, TNF-α, and matrix metalloproteinase-9 (MMP-9) for inflammation were examined using immunohistochemistry (IHC) and given a H-score. The remaining half of the kidneys were transported under a cold chain and stored at –85°C for biochemical measurements in renal tissues using enzyme-linked immunosorbent assay (ELISA) kits with rat enzyme-linked immunosorbent for determining the levels of IL-6, IL-1β, TNF-α, MMP-9, TAS, and TOS for ELISA.

HE staining

Specimens were taken from all kidneys and fixed in a 10% buffered neutral formaldehyde solution in the pathology laboratory. Sections were blocked in paraffin after routine tissue tracking. Then, 4- to 6-µm sections were cut from the blocks. Sections were stained with HE for histopathological evaluation. Ten randomly selected fields from all HE-stained sections were examined at 20 × magnification. The extent of lesions observed in the samples, including congestion, vacuolar degeneration, interstitial edema, proteinaceous material accumulation in the lumen, tubular separation, and necrosis, was scored on a scale ranging from 0 to 4. Scoring was based on the following criteria: 0 was normal; 1was mild lesions affecting 25% of the sample; 2 was lesions affecting 25–50% of the sample; 3 was lesions affecting 50–75% of the sample; and 4 was lesions affecting more than 75% of the sample. The samples were evaluated for glomerular changes, tubular dilatation, cellular vacuolization, presence of proteinaceous casts, necrosis, interstitial inflammation, and congestion.^23–27

Immunohistochemical staining

Indirect IHC was performed on formalin-fixed samples after deparaffinization and antigen retrieval. The sections were then incubated in Tris-buffered saline Tween-20 (TBST, pH 7.4) for 15 min and subsequently washed with TBST. Furthermore, 1% hydrogen peroxide (Lab Vision; Thermo Scientific) was administered for 30 min to avoid non-specific binding. Following the completion of the blocking procedure, the samples were treated with primary antibodies, including eNOS (Boster Bio., catalog number: A01604-2, diluted at a ratio of 1:250), caspase 3 (Thermo Scıentıfıc, catalog number: RB-1197-P0, diluted at a ratio of 1:100), TNF-α (Proteintech, catalog number:60291-1-Ig, diluted at a ratio of 1:300), IL-1β (Bioss, catalog number:bs-6319R, diluted at a ratio of 1:150), IL-6 (ST John’s, catalog number:STJ1110424, diluted at a ratio of 1:100), and MMP-9 (Boster Bio, catalog number: PA2140-2, diluted at a ratio of 1:100). The samples were then subjected to overnight incubation with the primary antibody at 4°C. The following day, cells were incubated with a biotin-conjugated secondary antibody (Lab Vision; Thermo Scientific, CA, USA) for 20 min at room temperature. Subsequently, sections were incubated with streptavidin-peroxidase for 20 min (Lab Vision, Thermo Scientific, CA, USA). Then, the sections underwent washing using TBST. The final step involved the development of a color reaction by incubating the sections with a chromogen substrate containing diaminobenzidine (DAB) for approximately 5–10 min at room temperature. Mayer’s hematoxylin was used for counterstaining. The H-score method was used to examine the semi-quantitative results obtained from immunohistochemical staining. Staining intensity was evaluated as weak (1), medium (2), and strong (3). For each intensity, three different microscopic fields were used to count cells. The following formula was used to determine the relevant score: H-score = ∑Pi (staining intensity + 1). Where the rate of labeled cells is presented as Pi, ranging from 0% to 100% for intensity values.^28,29

Biochemical examination

For biochemical examination, 2 mL blood samples were collected from rats in all groups by intracardiac puncture before they were sacrificed. Blood urea, calcium (Ca⁺²), creatinine, chloride (Cl^-), magnesium (Mg⁺²), phosphorus (P^-3), potassium (K⁺), sodium (Na⁺), and total protein (TP) levels in the serum and plasma samples were analyzed using an autoanalyzer. The levels of IL-1 (BT LAB, Rat ELISA Kits, Bioassay Technology Lab, Zhejiang, China, Cat No.: E0119Ra), IL-6 (BT LAB, Bioassay Technology Lab, Zhejiang, China, Cat No.: SEA079Ra), TNF-α (BT LAB, Rat ELISA Kits, Bioassay Technology Lab, Zhejiang, China, Cat No.: SEA133 Ra), TAS (Andygene, Rat ELISA Kits, Bioassay Technology Laboratory, Shanghai, China, Cat No.: AD3283Ra), TOS (BT LAB; Rat ELISA Kits, Bioassay Technology Lab, Zhejiang, China, Cat No.: E1512Ra,), NO (BT LAB; Cat No.: E0703Ra, Bioassay Technology Lab, Zhejiang, China), eNOS (Sunlong; Rat ELISA Kits, Sunlong Technology Co., LTD, China, Cat No.: SL1159Ra), and MMP-9 (YL BioNT; YL Biont, Shanghai YL Technology Co, Ltd, China Cat No.: YLA0585Ra) were analyzed using the ELISA kit.

Statistical analysis

Biochemical analyses: Groups were compared based on each parameter using the Kruskal–Wallis H test. Pair-wise comparisons were conducted using the Mann–Whitney U test. A p-value of less than 0.05 was considered statistically significant. Data were analyzed using SPSS version 26.0 (Armonk, NY: IBM Corp).

Histopathological analyses: Images were scored and averages were calculated. Data are presented as means ± standard deviations (n = 10). The one-way analysis of variance was used to analyze the differences among groups. A p-value of less than 0.05 was considered statistically significant.^30–32 GraphPad Prism 8.0 software (GraphPad, IL, CA, USA) was used for all statistical analyses.

Results

There was a significant increase in serum creatinine levels in the I/R group compared with the other groups (p < 0.05). Serum creatinine levels in the UR group were similar to those in the CR and SH groups (p > 0.05). Serum urea levels were higher in the I/R group (p < 0.05) than in the other groups. The serum urea levels in the UR group were lower (p < 0.05) than those in the I/R group. The serum urea levels in the UR and SH groups were similar (p > 0.05), yet significantly higher than those in the CR group (p < 0.05). Serum Na⁺ levels were similar in all the groups (p > 0.05). Serum K⁺ levels were higher in the UR group than in the other groups (p < 0.05). The serum Ca²⁺ levels in the CR and SH groups were similar. However, a significant decrease (p < 0.05) was found in the I/R group compared with the CR and SH groups (Table 1).

Table 1.

Comparison of biochemical measurements between groups.

Groups	Sodium	Potassium	Calcium	Urea	Creatinine	Phosphorus	Total protein	Albumin
CR Group	136,17±4,07	5,37b±0,99	10,85a±0,39	41,78b±4,11	0,44b±0,04	6,03b±0,86	6,36a±0,26	4,02a±0,08
SH Group	136,33±11,18	5,10b±0,67	10,86a±1,37	64,38ab±39,53	0,52b±0,11	8,22a±0,58	6,13a±0,67	4,20a±0,69
I/R Group	139,50±2,59	5,47b±0,67	10,41ab±0,17	86,37a±56,79	1,21a±0,26	8,07a±1,07	5,96a±0,24	3,38b±0,14
UR Group	138,17±5,23	6,53a±0,62	9,64b±0,49	58,73ab±13,62	0,46b±0,13	6,87b±1,09	4,70b±0,38	2,92c±0,21
p	0,397	0,010*	0,006*	0,019*	0,003*	0,007*	0,003*	0,001*

*: p<0.05 a, b: Differences between means with different letters in the same column are significant (p<0.05). SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UR, I/R+ Urapidil group.

The level of IL-6, a pro-inflammatory cytokine, showed a non-significant increase in the I/R group compared with the CR and SH groups, while an insignificant decrease was detected in the UR group. The level of TNF-α, a cytokine that plays a role in systemic inflammation and induces an acute phase reaction, increased significantly in the I/R group compared with the CR and SH groups (p < 0.05), and decreased significantly in the UR group compared with the I/R group (p < 0.05). The TP levels were lower in the UR group compared with the other groups (p < 0.05). Serum albumin levels were significantly lower in the I/R group compared with the CR and SH groups (p < 0.05). Similarly, serum albumin levels were lower in the UR group compared with the I/R group (p < 0.05). The IL-1β level, which is an inflammatory marker, displayed a significant increase in the I/R group compared with the CR and SH groups (p < 0.05). A significant decrease was observed in the UR group compared with the I/R group (p < 0.05). The MMP-9 levels were similar in all groups (p > 0.05). No significant differences in NO levels were observed between the groups (p > 0.05). A significant increase in eNOS levels was observed in the SH, I/R, and UR groups compared with the CR group (p < 0.05). However, a nonsignificant decrease was observed after UP administration compared with that after I/R (p > 0.05) (Table 2).

Table 2.

Comparison of inflammatory markers between groups.

	CR	SH	I/R	UR	p-value
IL-6 (pg/ml)	9,5778±0,51458	12,2222±2,457	14,9489±1,75646	12,0306±0,65955	0,152
TNF-α (pg/ml)	28,5833±1,57277b	26,6833±2,33401b	37,6660±1,74200a	32,0250±2,13925ab	0,007
IL-1β(pg/ml)	4,8567±0,36741b	5,6850±0,56106b	10,2983±0,78984a	9,5983±0,33170a	0,000
MMP-9 (ng/ml)	0,8260±0,01984	0,8722±0,02342	0,8708±0,02149	0,9090±0,02949	0,142
eNOS (ng/ml)	28,80b±2,80	34,55a±2,64	37,06a±4,45	34,25a±3,51	0,005*
TAS (U/ml)	5,3333±0,31287b	4,9356±0,13270bc	4,2900±0,39884c	6,7044±0,29501a	0,000
TOS (U/ml)	4,3020±0,32538	4,1400±0,32735	5,3167±0,39403	4,1017±0,45655	0,110

*: p<0.05 a, b: Differences between means with different letters in the same column are significant (p<0.05). SH, sham group; CR, control group; IR: group with ischemia-reperfusion (I/R) injury; UR, group given I/R+ Urapidil; IL-6, interleukin-6; TNF-α, tumor necrosis factor-alpha; IL-1β, interleukin-1 beta; MMP-9, matrix metalloproteinase-9; NO, nitric oxide; eNOS, endothelial nitric oxide synthase; TAS, total antioxidant status; TOS, total oxidant status.

A significant decrease in the TAS level was observed in the I/R group compared with the CR group (p < 0.05). In contrast, a significant increase was observed in the UR group compared with all other groups (p < 0.05). A nonsignificant increase (p > 0.05) in the TOS level was observed in the I/R group, whereas a nonsignificant decrease (p > 0.05) was observed in the UR group compared with the I/R group (Table 2).

The glomerular and tubular structures of the HE-stained samples were compared with those of the CR, less-damaged SH, and I/R groups. Damage, including Bowman space expansion in the glomerulus, degenerative and necrotic changes in tubular epithelial cells, inflammatory cell infiltration in the interstitial area, and vacuolization in the glomerular capillary bundle, increased significantly in the I/R group. No pathological deformities were observed in the kidneys, tubules, or glomeruli in the CR group. The SH group had a small amount of damage. Pathological distortions of the epithelial structure of the glomeruli and tubules were observed in the I/R group. Intensive degenerative structures and fluid accumulation associated with dilatation and edema were observed in the lumen, particularly in the epithelium of the proximal tubules surrounding the glomeruli. The lumen of the tubules was found to be extremely dilated owing to sloughing and deformation of the epithelium. The Bowman’s capsule and visceral cells were edematous, and the filtration space was dilated. The UR group had less damage than the I/R group (Figure 1). Pathological details were observed in all groups with HE staining (Figure 2). Statistical evaluations were performed by scoring the general morphological lesions after HE staining. The CR and SH groups had significantly higher numbers of lesion (p < 0.001) after I/R, which significantly (p < 0.05) improved after UP administration (Table 3).

Figure 1.

Transverse section of kidney cortex (figure above) and medulla with hematoxylin and eosin (HE) staining. Severe tubular damage, necrosis, tubular dilatation, vacuolization, loss of brush border, and hyaline cast formation in the tubular lumens (blue arrows) are observed for ischemia-reperfusion (I/R).

Figure 2.

HE staining of kidney samples from each group. In contrast to the CR and slightly damaged SH samples showing normal morphology, the damage is more pronounced in the I/R samples and less in the UP samples. HE, hematoxylin and eosin; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

Table 3.

General morphological disorders in hematoxylin and eosin (HE) staining were scored and statistically evaluated.

SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

As an oxidative stress marker, eNOS immunoreactivity increased in the CR and SH groups after I/R and decreased after UP administration (Figure 3). Statistical evaluation was conducted by scoring eNOS immunoreactivity using IHC. Immunoreactivity was significantly (p < 0.001) increased after I/R in comparison with that in the CR and decreased significantly (p < 0.05) in the less damaged SH samples after UP administration (Table 4).

Figure 3.

eNOS IHC of kidney samples from each group. When eNOS IHC was compared with the CR and SH groups, increased oxidative stress is seen in the I/R group which is reduced in the UP samples. eNOS, endothelial nitric oxide synthase; IHC, immunohistochemistry; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

Table 4.

Statistical evaluations were made with H-scoring in IHC eNOS markings.

IHC, immunohistochemistry; eNOS, endothelial nitric oxide synthase; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

Caspase 3, a marker of apoptosis, had increased basal immunoreactivity in the CR and SH samples after I/R, which decreased after UP administration (Figure 4). Caspase 3 immunoreactivity was scored, revealing that immunoreactivity significantly (p < 0.001) increased following I/R and decreased significantly (p < 0.05) after UP administration compared with that in the CR group. Less damage was observed in SH samples (Table 5).

Figure 4.

Comparison of Caspase 3 IHC between the kidney samples from each group. Details of Caspase 3 labeling were observed with IHC. IHC, immunohistochemistry; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

Table 5.

Statistical evaluations were made with h-scoring in IHC Caspase 3 labeling.

IHC, immunohistochemistry; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

TNF-α, a marker of inflammation, had increased basal immunoreactivity in the CR and SH samples following I/R, which decreased after UP administration (Figure 5). TNF-α immunoreactivity was scored, revealing that the immunoreactivity increased significantly (p < 0.001) following I/R compared with that in the CR group and significantly (p < 0.05) decreased in the less damaged SH samples after UP administration (Table 6).

Figure 5.

Comparison of TNF-α IHC between the kidney samples from each group. Details of TNF-α labeling were observed with IHC. TNF-α, tissue necrosis factor-alpha; IHC, immunohistochemistry; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

Table 6.

Statistical evaluations were made with h-scoring in IHC TNF-α labeling.

IHC, immunohistochemistry; TNF-α, tissue necrosis factor-alpha; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

IL-1β, an inflammatory marker, had increased basal immunoreactivity in the CR and SH samples following I/R, which decreased after UP administration (Figure 6). IL-1β immunoreactivity was scored, and statistical evaluations were made. Immunoreactivity increased significantly (p < 0.001) in the I/R group compared with the CR group and decreased significantly (p < 0.05) in the slightly damaged SH samples after UP administration (Table 7).

Figure 6.

Comparison of IL-1β IHC between the kidney samples from each group. Details of IL-1β labeling with IHC were observed at this figure. IL-1β, interleukin-1 beta; IHC, immunohistochemistry; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

Table 7.

Statistical evaluations were made with H-scoring in IHC IL-1β markings.

IHC, immunohistochemistry; IL-1β, interleukin-1 beta; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

IL-6, an inflammatory marker, had increased basal immunoreactivity in the CR and SH samples following I/R, which decreased after UP administration (Figure 7). IL6 immunoreactivity was scored using IHC, and statistical evaluations were made, revealing that the immunoreactivity in the I/R group increased significantly (p < 0.001) compared with that in the CR group and decreased significantly (p < 0.05) in the slightly damaged SH samples after UP administration (Table 8).

Figure 7.

Comparison of IL-6 IHC between the kidney samples from each group. IL-6, interleukin-6; IHC, immunohistochemistry; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

Table 8.

Statistical evaluations were made with H-scoring in IHC IL6 markings.

IHC, immunohistochemistry; IL-6, interleukin-6; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

MMP-9 had increased basal immunoreactivity in the CR and SH samples following I/R, which decreased after UP administration (Figure 8). Statistical evaluations were conducted by scoring MMP-9 immunoreactivity using IHC. The immunoreactivity of the I/R group was significantly higher (p < 0.001) than that of the CR group and decreased significantly (p < 0.05) in the slightly damaged SH samples after UP administration (Table 9).

Figure 8.

Comparison of MMP-9 IHC between the kidney samples from each group. Details of MMP-9 marking were observed with IHC. MMP-9, matrix metalloproteinase-9; IHC, immunohistochemistry; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

Table 9.

Statistical evaluations were made with H-scoring in IHC MMP-9 markings.

IHC, immunohistochemistry; MMP-9, matrix metalloproteinase-9; SH, sham group; CR, control group; I/R, ischemia-reperfusion injury; UP, urapidil.

Discussion

AKI is one of the leading causes of chronic kidney disease (CKD), accounting for 50–75% of deaths following severe kidney insults or organ transplantation.³³ Renal I/R injury, which involves the transient interruption of renal blood flow followed by reperfusion, is a major precipitant of AKI and worsens patient outcomes.^3,4 Despite various pharmacological interventions, AKI due to I/R has a poor prognosis, underscoring the urgent need for new treatment options. UP is an antihypertensive drug that acts as a peripheral alpha-1 adrenergic receptor blocker and has a central 5-HT1A agonist effects.⁸ In this study, we investigated the anti-apoptotic, antioxidant, anti-inflammatory, and matrix-regulatory effects of UP using an experimental renal I/R model. We found that UP treatment significantly ameliorated I/R-induced oxidative stress, inflammation, and apoptosis in kidneys. Improvements in the TAS/TOS balance and histopathological protection observed in UP-treated kidneys support the notion that UP can mitigate I/R injury. Our results suggest that UP may serve as a potential therapeutic adjuvant for renal I/R injury in the kidney and possibly in other organs. Importantly, these protective effects were achieved with a low microgram-range dose of UP, which is an order of magnitude lower than the doses used in previous renal I/R studies. To the best of our knowledge, this is the first demonstration that UP can be effective at a low dose in the context of renal I/R. The ability of even a microgram dose of UP to confer significant renoprotection highlights the potency of its pharmacological actions and suggests a wider therapeutic window with potentially fewer side effects. This is a novel finding that could have practical implications for clinical translation.

Numerous previous studies have investigated the pathogenesis of renal I/R injury and potential therapeutic interventions, highlighting elevated serum creatinine and urea as primary markers of renal dysfunction following I/R.^1,2,4,6 Consistent with these findings, our study demonstrated significantly increased serum creatinine and urea levels in the I/R group. Notably, UP treatment substantially reduced these elevations, suggesting an improvement in renal function. This result aligns well with the limited available literature on UP’s renal protective effects, such as the findings of Erdoğan et al.,¹⁰ who also reported significant improvement in renal function following UP administration.

Renal I/R injury is strongly associated with oxidative stress caused by excessive ROS production and/or inadequate antioxidant defenses.⁷ Excessive ROS generation triggers lipid peroxidation, DNA damage, and mitochondrial dysfunction, leading to cell injury and death. It also initiates an inflammatory cascade: post-ischemic tissue releases large amounts of cytokines such as TNF-α, IL-6, and IL-1β, which recruit inflammatory cells and amplify tissue injury. IL-1β, IL-6, and TNF-α are well-known mediators of renal damage in I/R injury.^34–36 In our study, we observed that IL-1β and TNF-α levels increased with I/R and were significantly reduced by UP administration, both in tissue homogenates and at the tissue level (IHC). Although IL-6 levels did not show a significant change in the ELISA measurements, their immunoreactivity was elevated in I/R kidneys and decreased with UP, suggesting that localized cytokine production in the kidney was curbed by UP. These results clearly demonstrate the anti-inflammatory properties of UP in the context of renal I/R, as UP blunted the upsurge of key inflammatory cytokines (TNF-α, IL-1β, and IL-6) that drive AKI progression. This is consistent with previous reports on UP’s anti-inflammatory effects in other I/R models.^8,9

Additionally, our findings highlight the impact of UP on matrix remodelling processes during I/R injury, which, to date, has been a relatively underexplored aspect of UP. MMP-9 (gelatinase B, a type IV collagenase) is an enzyme that degrades components of the extracellular matrix (ECM) and activates certain cytokines and chemokines, thereby playing a central role in tissue remodeling and inflammation.³⁷ Previous studies have reported varying results regarding MMP-9 levels.³⁸ Some experimental studies have shown that MMP-9 activity increases during renal I/R injury, contributing to tissue damage; however, other studies have reported differences depending on the model and timing. Notably, excessive MMP-9 (often released by infiltrating neutrophils) has been implicated in exacerbating I/R injury by promoting inflammation and ECM proteolysis.³⁷ In an in vitro hypoxia-reoxygenation model, Dong et al. demonstrated that an acute surge of neutrophil-derived MMP-9 triggers inflammatory damage and that inhibiting MMP-9 can mitigate such injury. In our study, we found no significant change in overall tissue MMP-9 levels among the groups using ELISA, suggesting that systemic or total renal MMP-9 content remained similar within 24 h. However, IHC revealed a clear increase in MMP-9 expression in renal tubular and interstitial cells after I/R, which was significantly attenuated by UP treatment. Hence, UP effectively reduced MMP-9 immunoreactivity in kidneys following I/R injury. By decreasing MMP-9 levels, UP may help to preserve the integrity of the basement membrane and ECM in renal tissues, thereby preventing excessive tissue degradation and inflammatory cell infiltration. This matrix-preserving action provides an additional mechanism by which UP protects the kidneys. To the best of our knowledge, this is the first study to show that UP can downregulate MMP-9 expression in renal I/R injury, thereby contributing to tissue protection through a matrix-regulatory effect. This is an original contribution of our study, distinguishing it from earlier studies, which largely focused on inflammatory cytokines and oxidative stress markers. In summary, the ability of UP to modulate MMP-9, coupled with its anti-inflammatory and antioxidant effects, suggests a multifaceted protective profile. By inhibiting both the upstream mediators of injury (ROS and cytokines) and downstream effectors like MMP-9 that drive tissue remodelling, UP provides comprehensive protection against I/R-induced renal damage. This dual action (anti-inflammatory and anti-remodelling) is a novel insight that enhances our understanding of how UP confers renoprotection.

Another important aspect of our study was the dose of UP used. Unlike previous investigations that administered UP in milligram per kilogram doses before ischemia (e.g., 0.5–5 mg/kg in rodent models),⁹ we used a much smaller dose (30 µg/kg bolus plus infusion). Despite the low dose, robust protective effects were observed. Although effective, high doses of UP can potentially cause significant hemodynamic changes (owing to its antihypertensive action) or side effects.⁸ The success of the low-dose regimen in our study suggests that the renoprotective effects of UP can be achieved with minimal dosing, minimizing off-target effects on blood pressure. This low-dose efficacy is particularly advantageous for potential clinical applications as it indicates that patients may benefit from the protective effects of UP without the risk of profound hypotension or other dose-related adverse effects. It also raises interesting questions about the mechanisms involved. Low-dose UP may preferentially trigger cytoprotective cellular pathways (such as 5-HT1A receptor-mediated signaling or mild adrenergic blockade that preconditions tissues) rather than exerting broad systemic effects.

The antioxidant effects of UP observed in our study (increase in TAS and reduction in oxidative damage markers) align with previous findings that UP activates antioxidant defenses. Improved TAS in UP-treated kidneys indicated enhanced total antioxidant capacity, which is beneficial for counteracting I/R-induced ROS surges. Additionally, UP’s reduction of eNOS immunostaining, an oxidative stress marker,³⁹ in I/R kidneys suggests a normalization of endothelial function. Since eNOS can be upregulated by shear stress and oxidant stimuli during reperfusion, its reduction by UP may reflect decreased oxidative stress in endothelial cells or a stabilization of endothelial nitric oxide production. This effect contributed to better perfusion and less vascular injury in the UP-treated group, thereby complementing the direct cellular protective effects.

Furthermore, UP significantly reduced caspase-3, an indicator of inflammation and apoptosis,⁴⁰ and its activation in renal tissue, demonstrating an anti-apoptotic effect. Apoptosis is a key mechanism of cell loss in I/R injury, and limiting apoptosis helps preserve nephronal integrity. By reducing caspase-3, UP helps maintain cell survival in the post-ischemic kidney, which likely contributed to the improved renal function and histology observed.

Overall, our study highlights two novel and clinically relevant findings. First, we demonstrated that UP is effective at very low microgram doses, conferring significant protection against renal I/R injury. Second, we established that UP modulates MMP-9 expression, thereby influencing ECM remodeling during I/R injury. These findings not only extend the pharmacological profile of UP, but also open new avenues for its potential clinical applications. The efficacy observed at low doses suggests that the protective mechanism of UP may involve high-affinity receptor targets or highly sensitive signaling pathways that require minimal drug concentrations for activation. Additionally, the observed modulation of MMP-9 underscores a protective mechanism aimed at preserving tissue architecture, potentially reducing the risk of fibrosis and subsequent CKD following acute I/R injury.

The results of this study are particularly promising from a translational perspective. UP is an established antihypertensive medication with a well-characterized human safety profile,¹⁰ facilitating its potential repurposing for renal protection in clinical settings, such as kidney transplantation, vascular surgery, or AKI management. Importantly, demonstrating renal protection at significantly lower doses than those typically used for hypertension control highlights an essential therapeutic advantage: effective renal protection can potentially be achieved without substantial systemic blood pressure alterations. Consequently, UP may serve as a viable adjunctive treatment for patients at risk of renal I/R injury, offering protective benefits while minimizing cardiovascular risk. Furthermore, through its inhibitory effects on MMP-9, UP may attenuate post-ischemic inflammatory responses and fibrosis, thereby improving long-term renal outcomes. Although additional clinical studies are necessary to refine dosing strategies and optimal timing of administration, our study provides robust proof-of-concept evidence for the nephroprotective effects of UP and introduces a novel concept of matrix protection via MMP-9 modulation. These mechanistic insights could significantly enhance the therapeutic design of combined approaches aimed at preventing and treating AKI.

Conclusion

In conclusion, we found that a low microgram dose of UP (30 µg/kg with infusion) significantly protects against renal I/R injury by reducing oxidative stress, apoptosis, inflammation, and downregulating MMP-9 expression. Our study uniquely demonstrated the efficacy of UP at minimal doses and its novel role in modulating ECM remodeling through MMP-9 inhibition. These findings suggest that UP could safely be repurposed in clinical scenarios such as kidney transplantation or vascular surgery, providing organ protection without substantial hemodynamic alterations. In addition, its matrix-protective effects may improve long-term renal outcomes by reducing fibrosis. Future clinical trials are warranted to further evaluate the nephroprotective effects of UP.

Footnotes

ORCID iD

Hazen Sarıtaş

Ethical considerations

The Afyon Kocatepe University Experimental Animal Ethics Committee approved the study (Aproval No: 49533702/101, Dated 11.10.2023).

Author contributions

H.S, Z.K.S and A.B contributed to writing–original draft, methodology, and conceptualization. H.A.K and F.G contributed to writing–review & editing. B.D, Y.K, B.G.E and Z.D contributed to software and resources

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

The datasets and supporting the findings of this study are available from the corresponding author, Hazen Sarıtaş, upon reasonable request.*

References

Malek

Nematbakhsh

. Renal ischemia/reperfusion injury; from pathophysiology to treatment. Journal of renal injury prevention 2015; 4: 20–27. https://doi.org/10.12861/jrip.2015.06

M-Y

Yiang

G-T

Liao

W-T

, et al. Current mechanistic concepts in ischemia and reperfusion injury. Cellular Physiology and Biochemistry 2018; 46: 1650–1667. https://doi.org/10.1159/000489241

Sharfuddin

Molitoris

. Pathophysiology of ischemic acute kidney injury. Nature Reviews Nephrology 2011; 7: 189–200. https://doi.org/10.1038/nrneph.2011.16

Gaut

Liapis

. Acute kidney injury pathology and pathophysiology: a retrospective review. Clinical Kidney Journal 2021; 14: 526–536. https://doi.org/10.1093/ckj/sfaa142

Nath

Norby

. Reactive oxygen species and acute renal failure. The American journal of medicine 2000; 109: 665–678. https://doi.org/10.1016/s0002-9343(00)00612-4

Chen

C-C

Liu

Z-M

Wang

H-H

, et al. Effects of ulinastatin on renal ischemia-reperfusion injury in rats. Acta Pharmacologica Sinica 2004; 25: 1334–1340.

Kaushal

Chandrashekar

Juncos

. Molecular interactions between reactive oxygen species and autophagy in kidney disease. International journal of molecular sciences 2019; 20: 3791. https://doi.org/10.3390/ijms20153791

Güler

Tanyeli

Erdoğan

, et al. Urapidil alleviates ovarian torsion detorsion injury via regulating oxidative stress, apoptosis, autophagia, and inflammation. Iranian Journal of Basic Medical Sciences 2021; 24: 935–942. https://doi.org/10.22038/ijbms.2021.57196.12736

Ozturk

Guzel Erdogan

Tanyeli

, et al. The protective effects of urapidil on lung tissue after intestinal ischemia-reperfusion injury. Turkish Journal of Biochemistry 2019; 44: 539–548. https://doi.org/10.1515/tjb-2018-0286

10.

Erdoğan

Tanyeli

Güler

, et al. Beneficial Effects of Urapidil against Renal Ischemia Reperfusion-Related Renal Injury. Southern Clinics of Istanbul Eurasia 2022; 33.

11.

Mohamed

Morsy

Mohamed

, et al. Paeonol protects against testicular ischaemia reperfusion injury in rats through inhibition of oxidative stress and inflammation. Andrologia 2020; 52: e13599. https://doi.org/10.1111/and.13599

12.

Z-M

. Role of antioxidants in preventing testicular ischemia-reperfusion injury: a narrative review. European Review for Medical & Pharmacological Sciences 2022; 26: 9126–9143. https://doi.org/10.26355/eurrev_202212_30663

13.

Chung

Lan

. Chemokines in renal injury. Journal of the American Society of Nephrology 2011; 22: 802–809. https://doi.org/10.1681/ASN.2010050510

14.

Kabasakal

Şehirli

Çetinel

, et al. Protective effect of aqueous garlic extract against renal ischemia/reperfusion injury in rats. Journal of Medicinal Food 2005; 8: 319–326. https://doi.org/10.1089/jmf.2005.8.319

15.

Percie du Sert

Hurst

Ahluwalia

, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Journal of Cerebral Blood Flow & Metabolism 2020; 40: 1769–1777. https://doi.org/10.1177/0271678X20943823

16.

National Research Council, Division on Earth and Life Studies

Guide for the care and use of laboratory animals. The National Academies 2010.

17.

Cui

Lin

Sun

, et al. Curcumin protects against renal ischemia/reperfusion injury by regulating oxidative stress and inflammatory response. Evidence Based Complementary and Alternative Medicine 2021; 2021: 8490772. https://doi.org/10.1155/2021/8490772

18.

Yeung

Richir

Hanrath

, et al. Infrarenal aortic‐clamping after renal ischaemia aggravates acute renal failure. European journal of clinical investigation 2011; 41: 605–615. https://doi.org/10.1111/j.1365-2362.2010.02448.x

19.

Güney

Kocman

Ozatik

, et al. The effect of fucoidin on kidney and lung injury in a rat infrarenal aortic ischemia-reperfusion model. Perfusion 2022; 37: 198–207. https://doi.org/10.1177/0267659120982839

20.

Kip

Köksal

Yığman

, et al. Organ-protective effects of fullerenol and desflurane in a rat model of ischemia–reperfusion injury. Scientific Reports 2025; 15: 40138. https://doi.org/10.1038/s41598-025-23812-3

21.

Sevil

Becit

, et al. Protective effects of curcumin on kidney tissue in ischemiareperfusion injury in rats. Turkish Journal of Vascular Surgery 2023; 32: 71–77. https://doi.org/10.9739/tjvs.2023.03.08

22.

Tort

Sevil

, et al. Protective effects of safranal on kidney tissue in a rat model of distant ischemiareperfusion injury with infrarenal aortic occlusion. Turkish Journal of Medical Sciences 2023; 53: 1574–1581. https://doi.org/10.55730/1300-0144.5726

23.

Erbatur

Sezen

ŞC

Bayraktar

, et al. Effects of dexmedetomidine on renal tissue after lower limb ischemia reperfusion injury in streptozotocin induced diabetic rats. Libyan Journal of Medicine 2017; 12: 1270021. https://doi.org/10.1080/19932820.2017.1270021

24.

Şengel

Köksal

Dursun

, et al. Effects of dexmedetomidine administered through different routes on kidney tissue in rats with spinal cord ischaemia–reperfusion injury. Drug Design, Development and Therapy 2023; 16: 2229–2239. https://doi.org/10.2147/DDDT.S361618

25.

Moreira Neto

Francisco Neto

Moreira

FMDR

, et al. Effects of dietary creatine supplementation on kidney and striated skeletal muscles of rats submitted to ischemia and reperfusion of hind limbs. Acta Cirúrgica Brasileira 2021; 36: e360305. https://doi.org/10.1590/ACB360305

26.

Altuncı

Aydoğdu

Açıkgöz

, et al. New psychoactive substance 5-MeO-MiPT in vivo acute toxicity and hystotoxicological study. Balkan Medical Journal 2021; 38: 34–42. https://doi.org/10.4274/balkanmedj.galenos.2020.2019.11.68

27.

Moreira Neto

Souza Júnior

SSD

Capelozzi

, et al. Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. Acta cirurgica brasileira 2012; 27: 783–788. https://doi.org/10.1590/s0102-86502012001100007

28.

Tseng

C-C

Wang

M-C

Lin

W-H

, et al. Role of class II P fimbriae and cytokine response in the pathogenesis of Escherichia coli kidney infection in diabetic mice. Journal of Microbiology, Immunology and Infection 2018; 51: 492–499. https://doi.org/10.1016/j.jmii.2017.06.003

29.

Hosseini

Shirazpour

Zangiabadizadeh

, et al. High-Intensity Interval Training Ameliorates Tramadol-Induced Nephrotoxicity and Oxidative Stress in Experimental Rats. Cureus 2024; 16.

30.

Hassan

Gharib

Hagag

, et al. Restoration of renal hemodynamics and functions by Nigella sativa administration in dinitrophenol-induced hypoxia in rat’s animal model. International Journal of Health Sciences 2024; 18: 22–31.

31.

Aziz

Ahmed

Shaker

, et al. Portulaca oleracea L seed extracts counteract diabetic nephropathy through SDF-1/IL10/PPARγ–mediated tuning of keap1/Nrf2 and NF-κB transcription in Sprague Dawley rats. Diabetology & Metabolic Syndrome 2024; 16: 119. https://doi.org/10.1186/s13098-024-01330-y

32.

Yang

Zhang

X-M

Tarnawski

, et al. Dietary nitrate attenuates renal ischemia-reperfusion injuries by modulation of immune responses and reduction of oxidative stress. Redox biology 2017; 13: 320–330. https://doi.org/10.1016/j.redox.2017.06.002

33.

Kellum

Romagnani

Ashuntantang

, et al. Acute kidney injury. Nature reviews Disease primers 2021; 7: 52. https://doi.org/10.1038/s41572-021-00284-z

34.

Baud

Ardaillou

. Reactive oxygen species: production and role in the kidney. American Journal of Physiology-Renal Physiology 1986; 251: F765–F776. https://doi.org/10.1152/ajprenal.1986.251.5.F765

35.

Irazabal

Torres

. Reactive oxygen species and redox signaling in chronic kidney disease. Cells 2020; 9: 1342. https://doi.org/10.3390/cells9061342

36.

De Vries

Lindeman

Tsikas

, et al. Early renal ischemia-reperfusion injury in humans is dominated by IL-6 release from the allograft. American Journal of Transplantation 2009; 9: 1574–1584. https://doi.org/10.1111/j.1600-6143.2009.02675.x

37.

Dong

Zhao

Man

, et al. MMP-9-mediated regulation of hypoxia-reperfusion injury-related neutrophil inflammation in an in vitro proximal tubular cell model. Renal Failure 2021; 43: 900–910. https://doi.org/10.1080/0886022X.2021.1930558

38.

Cavdar

Ozbal

Celik

, et al. The effects of alpha-lipoic acid on MMP-2 and MMP-9 activities in a rat renal ischemia and re-perfusion model. Biotechnic & Histochemistry 2014; 89: 304–314. https://doi.org/10.3109/10520295.2013.847498

39.

Thurman

. Triggers of inflammation after renal ischemia/reperfusion. Clinical immunology 2007; 123: 7–13. https://doi.org/10.1016/j.clim.2006.09.008

40.

Sun

Zhang

, et al. Atractylenolide I alleviates ischemia/reperfusion injury by preserving mitochondrial function and inhibiting caspase-3 activity. Journal of International Medical Research 2021; 49: 0300060521993315. https://doi.org/10.1177/0300060521993315

Low-dose urapidil mitigates renal ischemia-reperfusion injury through matrix metalloproteinase-9 inhibition and anti-inflammatory effects

Abstract

Objective

Methods

Results

Conclusion

Keywords

Introduction

Materials and methods

Study design

Ethical approval

Anesthesia

Surgical procedure

Groups and the I/R model

Euthanasia

Source of animals

Histopathological examination

HE staining

Immunohistochemical staining

Biochemical examination

Statistical analysis

Results

Discussion

Conclusion

Footnotes

ORCID iD

Ethical considerations

Author contributions

Funding

Declaration of conflicting interests

Data Availability Statement

References